Pharma · Private company
Novartis Vaccines
Track this companyFree. Adds Novartis Vaccines to your Dealase workspace and tells you when its record changes.
Clinical trials100 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline14
- Cell culture-derived influenza vaccinePhase 3 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Egg-derived influenza virus vaccinePhase 3 · InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- TIVc_LOT APhase 3 · Prophylaxis: InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- TIVc_LOT BPhase 3 · Prophylaxis: InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- TIVc_LOT CPhase 3 · Prophylaxis: InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- TIVfPhase 3 · Prophylaxis: InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Adjuvanted H5N1 pandemic influenza vaccinePhase 2 · Pandemic H5N1 InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.Phase 2 · Invasive Meningococcal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.Phase 2 · Invasive Meningococcal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.Phase 2 · Invasive Meningococcal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- H7N9c high dose with adjuvantPhase 1 · H7N9 InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- H7N9c high dose without adjuvantPhase 1 · H7N9 InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- H7N9c low dose with adjuvantPhase 1 · H7N9 InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
- H7N9c medium dose with adjuvantPhase 1 · H7N9 InfluenzaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent VaccinePHASE2 · COMPLETED · started Nov 20, 2014ClinicalTrials.gov NCT02270944 · fetched Nov 12, 2026
- Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult SubjectsPHASE3 · COMPLETED · started Sep 1, 2014ClinicalTrials.gov NCT02256488 · fetched Nov 12, 2026
- Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant WomenPHASE2 · COMPLETED · started Mar 18, 2014ClinicalTrials.gov NCT02046148 · fetched Nov 12, 2026
- Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.PHASE3 · COMPLETED · started Nov 1, 2013ClinicalTrials.gov NCT01964989 · fetched Nov 12, 2026
- Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 YearsPHASE1 · COMPLETED · started Aug 1, 2013ClinicalTrials.gov NCT01928472 · fetched Nov 12, 2026
- Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in ChildrenPHASE2 · COMPLETED · started Jan 1, 2013ClinicalTrials.gov NCT01776554 · fetched Nov 12, 2026
- Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly SubjectsPHASE2 · COMPLETED · started Jan 1, 2013ClinicalTrials.gov NCT01766921 · fetched Nov 12, 2026
- Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young AdultsPHASE2 · COMPLETED · started Aug 1, 2011ClinicalTrials.gov NCT01272180 · fetched Nov 12, 2026
- Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)PHASE1 · COMPLETED · started Nov 1, 2008ClinicalTrials.gov NCT00812019 · fetched Nov 12, 2026
- Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult SubjectsPHASE3 · COMPLETED · started Oct 1, 2007ClinicalTrials.gov NCT00630331 · fetched Nov 12, 2026